NanoViricides Beat Consensus Estimates

NanoViricides (NNVC) reported a loss of $0.10 per share on revenue of $0.00 million for the fiscal fourth quarter ended June 2026. The consensus estimate was a loss of $0.11 per share. The company beat consensus estimates by 9.09%.

Nanoviricides Inc a development stage nano-biopharmaceutical company, engages in the discovery, development, and commercialization of anti-viral therapeutics primarily in the United States.